Thompson Siegel & Walmsley LLC United Therapeutics Corp Transaction History

Thompson Siegel & Walmsley LLC

$6.71 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$205.19 - $232.99 $3,488 - $3,960	-17 Reduced 5.17%	312 $69,000
Q1 2023 May 11, 2023	SELL	$212.99 - $276.17 $40,255 - $52,196	-189 Reduced 36.49%	329 $74,000
Q4 2022 Feb 10, 2023	BUY	$205.95 - $280.43 $106,682 - $145,262	518 New	518 $144,000
Q3 2022 Oct 25, 2022	SELL	$203.3 - $244.17 $5.22 Million - $6.27 Million	-25,664 Reduced 19.81%	103,865 $21.7 Million
Q2 2022 Jul 22, 2022	SELL	$174.81 - $241.14 $1.58 Million - $2.18 Million	-9,058 Reduced 6.54%	129,529 $30.5 Million
Q1 2022 Apr 26, 2022	BUY	$166.16 - $213.96 $838,775 - $1.08 Million	5,048 Added 3.78%	138,587 $24.9 Million
Q4 2021 Feb 09, 2022	SELL	$184.32 - $216.08 $4.12 Million - $4.83 Million	-22,373 Reduced 14.35%	133,539 $28.9 Million
Q3 2021 Nov 05, 2021	SELL	$179.86 - $214.88 $21.5 Million - $25.7 Million	-119,590 Reduced 43.41%	155,912 $28.8 Million
Q2 2021 Aug 09, 2021	SELL	$170.47 - $211.93 $14.1 Million - $17.6 Million	-82,982 Reduced 23.15%	275,502 $49.4 Million
Q1 2021 May 07, 2021	SELL	$153.94 - $174.85 $2.06 Million - $2.34 Million	-13,369 Reduced 3.6%	358,484 $60 Million
Q4 2020 Feb 08, 2021	SELL	$101.87 - $151.79 $5.88 Million - $8.77 Million	-57,746 Reduced 13.44%	371,853 $56.4 Million
Q3 2020 Nov 12, 2020	SELL	$99.9 - $121.13 $1.44 Million - $1.75 Million	-14,428 Reduced 3.25%	429,599 $43.4 Million
Q2 2020 Aug 11, 2020	SELL	$92.74 - $125.82 $15.5 Million - $21.1 Million	-167,453 Reduced 27.38%	444,027 $53.7 Million
Q1 2020 May 12, 2020	SELL	$79.39 - $115.35 $17.9 Million - $26 Million	-225,834 Reduced 26.97%	611,480 $58 Million
Q4 2019 Feb 07, 2020	SELL	$78.31 - $95.34 $544,097 - $662,422	-6,948 Reduced 0.82%	837,314 $73.8 Million
Q3 2019 Nov 12, 2019	SELL	$74.85 - $85.99 $1.57 Million - $1.8 Million	-20,942 Reduced 2.42%	844,262 $67.3 Million
Q2 2019 Aug 12, 2019	BUY	$76.06 - $120.81 $33.2 Million - $52.8 Million	437,094 Added 102.1%	865,204 $67.5 Million
Q1 2019 May 13, 2019	SELL	$107.15 - $126.84 $2.36 Million - $2.79 Million	-22,027 Reduced 4.89%	428,110 $50.2 Million
Q4 2018 Feb 11, 2019	SELL	$101.4 - $128.73 $6.32 Million - $8.02 Million	-62,290 Reduced 12.16%	450,137 $49 Million
Q3 2018 Nov 08, 2018	SELL	$113.81 - $129.46 $5.31 Million - $6.04 Million	-46,680 Reduced 8.35%	512,427 $65.5 Million
Q2 2018 Aug 09, 2018	BUY	$101.14 - $118.31 $1.68 Million - $1.97 Million	16,638 Added 3.07%	559,107 $63.3 Million
Q1 2018 May 08, 2018	SELL	$107.21 - $151.94 $4.7 Million - $6.67 Million	-43,885 Reduced 7.48%	542,469 $61 Million
Q4 2017 Feb 09, 2018	SELL	$118.58 - $151.28 $477,640 - $609,355	-4,028 Reduced 0.68%	586,354 $86.8 Million
Q3 2017 Nov 08, 2017	BUY	$114.6 - $136.81 $1.06 Million - $1.27 Million	9,271 Added 1.6%	590,382 $69.2 Million
Q2 2017 Aug 09, 2017	BUY	N/A	581,111	581,111 $75.4 Million

Others Institutions Holding UTHR

# of Institutions

676

Shares Held

42.1M

Call Options Held

194K

Put Options Held

295K

Black Rock Inc. New York, NY

5.47M
Shares

$2.03 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

4.41M
Shares

$1.64 Billion
0.03% of portfolio
Wellington Management Group LLP Boston, MA

3.17M
Shares

$1.18 Billion
0.2% of portfolio
Avoro Capital Advisors LLC New York, NY

2.86M
Shares

$1.06 Billion
15.42% of portfolio
State Street Corp Boston, MA

2.24M
Shares

$832 Million
0.03% of portfolio

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.9B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thompson Siegel & Walmsley LLC, based on Form 13F filings with the SEC.

News

Stay updated on Thompson Siegel & Walmsley LLC with notifications on news.

Account